Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
TLSA logo TLSA
Upturn stock ratingUpturn stock rating
TLSA logo

Tiziana Life Sciences Ltd (TLSA)

Upturn stock ratingUpturn stock rating
$1.69
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

09/12/2025: TLSA (3-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Analysis of Past Performance

Type Stock
Historic Profit -7.69%
Avg. Invested days 26
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 09/12/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 186.96M USD
Price to earnings Ratio -
1Y Target Price 3
Price to earnings Ratio -
1Y Target Price 3
Volume (30-day avg) -
Beta 0.11
52 Weeks Range 0.63 - 1.91
Updated Date 06/29/2025
52 Weeks Range 0.63 - 1.91
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.11

Earnings Date

Report Date 2025-06-23
When After Market
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -84.13%
Return on Equity (TTM) -250.49%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 183338371
Price to Sales(TTM) -
Enterprise Value 183338371
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -5.98
Shares Outstanding 116848000
Shares Floating 63394363
Shares Outstanding 116848000
Shares Floating 63394363
Percent Insiders 43.06
Percent Institutions 2.73

ai summary icon Upturn AI SWOT

Tiziana Life Sciences Ltd

stock logo

Company Overview

overview logo History and Background

Tiziana Life Sciences Ltd is a biotechnology company founded in 2014. It focuses on developing innovative therapeutics for oncology, inflammation, and infectious diseases. The company has evolved from a focus on monoclonal antibodies to include small molecule research and development.

business area logo Core Business Areas

  • Immunotherapy: Development of monoclonal antibodies for cancer and inflammatory diseases.
  • Targeted Therapeutics: Development of small molecule drugs targeting specific disease pathways.
  • COVID-19 Therapeutics: Development of therapies to treat COVID-19 and its related complications.

leadership logo Leadership and Structure

The leadership team consists of a CEO, CFO, CSO, and a board of directors. The company structure is organized around research, development, and commercialization divisions.

Top Products and Market Share

overview logo Key Offerings

  • Foralumab: An anti-CD3 monoclonal antibody in development for Crohn's disease, non-alcoholic steatohepatitis (NASH), and other inflammatory and autoimmune diseases. No current market share data. Competitors include AbbVie (Humira) and Janssen (Stelara).
  • Milciclib: A small molecule inhibitor of cyclin-dependent kinases (CDKs) in development for hepatocellular carcinoma (HCC). No current market share data. Competitors include Bayer (Nexavar) and Eisai (Lenvima).

Market Dynamics

industry overview logo Industry Overview

The biotechnology industry is experiencing rapid growth, driven by advancements in genomics, proteomics, and personalized medicine. The market is highly competitive, with many companies vying for market share.

Positioning

Tiziana Life Sciences Ltd is positioned as a clinical-stage biotechnology company with a focus on innovative therapeutics. Its competitive advantages include its novel pipeline of drug candidates and its experienced management team.

Total Addressable Market (TAM)

The TAM for oncology, inflammation, and infectious diseases is estimated to be in the hundreds of billions of dollars. Tiziana Life Sciences Ltd is positioned to capture a portion of this market with its targeted therapies.

Upturn SWOT Analysis

Strengths

  • Novel pipeline of drug candidates
  • Experienced management team
  • Focus on unmet medical needs
  • Strong intellectual property portfolio

Weaknesses

  • Limited financial resources
  • Reliance on clinical trial success
  • Lack of commercial infrastructure
  • Small Market Cap

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion into new therapeutic areas
  • Acquisition of complementary technologies
  • Favorable regulatory environment

Threats

  • Competition from larger pharmaceutical companies
  • Clinical trial failures
  • Regulatory hurdles
  • Economic downturn

Competitors and Market Share

competitor logo Key Competitors

  • ABBV
  • JNJ
  • GILD
  • BMY

Competitive Landscape

Tiziana Life Sciences Ltd faces significant competition from larger pharmaceutical companies with established products and greater resources. However, its innovative pipeline and targeted therapies offer potential competitive advantages.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been driven by the advancement of its pipeline candidates through clinical trials.

Future Projections: Future growth is dependent on the successful completion of clinical trials and the potential commercialization of its drug candidates. Analyst estimates vary widely.

Recent Initiatives: Recent initiatives include the advancement of Foralumab into Phase 2 trials for Crohn's disease and NASH, and the development of inhaled Foralumab for COVID-19.

Summary

Tiziana Life Sciences is a high-risk, high-reward clinical-stage biotech company with a novel pipeline. Its success hinges on positive clinical trial outcomes, and its limited financial resources pose a challenge. While the company has an innovative portfolio, it needs strategic partnerships and acquisitions to thrive given its size and competition from big pharma.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Analyst reports
  • Market research reports

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. The biotechnology industry is inherently risky, and past performance is not indicative of future results.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Tiziana Life Sciences Ltd

Exchange NASDAQ
Headquaters -
IPO Launch date 2000-03-24
CEO & Executive Director Dr. Ivor R. Elrifi Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 9
Full time employees 9

Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.